Riders · Animal Health Commission · Article VI: Natural Resources

Cattle Fever Tick Mitigation Clinical Trials

Rider 10 in the 2026-27 Act, page VI-16 · was rider 9

2028-29 request. Animal Health Commission has asked to delete this rider. What it asked for. A request, not law.

Through the session

  1. 2024-25 Act In current law rider 10
  2. Introduced (Senate) Amended rider 9
  3. Introduced (House) Amended rider 9
  4. Senate substitute Unchanged rider 9
  5. House substitute Unchanged rider 9
  6. House passed Unchanged rider 9
  7. Conference Unchanged rider 9
  8. 2026-27 Act Unchanged rider 10

Pick any two steps to compare their wording.

What changed in the text

2024-25 Act → Introduced (House): 10 passages changed.

Cattle Fever Tick Mitigation Clinical Trials. (a) Amounts appropriated above to the Animal Health Commission (TAHC) in Strategy A.1.2, Diagnostic/Epidemiological Support Services, include $87,000 in fiscal year 2024 and $229,000 $30,000 in fiscal year 2025 2026 from the General Revenue Fund for the purposes of conducting completing cattle fever tick mitigation clinical trials that would evaluate the efficacy of three eprinomectin regimens for cattle fever tick control to determine if less frequent treatments can be used to effectively mitigate fever ticks. Any unexpended balances remaining as of August 31, 2024, 2026, are appropriated in the fiscal year beginning September 1, 2024, 2026, for the same purposes. (b) Out of amounts identified in subsection (a), TAHC would evaluate dosing and withdraw periods in weaned beef heifers in phase one. (c) Out of amounts identified in subsection (a), TAHC shall transfer up to $40,000 of the funds appropriated by this rider in fiscal year 2025 to a Texas state University through an interagency contract to assist in conducting phase two of the clinical trials that would evaluate repeated dosing and withdraw periods in full herd settings.

Removed words are struck through; added words are underlined. Sources: 2024-25 Act · Introduced (House).

Every version: numbers, statuses and source pages
VersionRider Against the version beforeAgainst the current budget Source
2024-25 ActGeneral Appropriations Act, 2024-25 Biennium 10 First version — Page VI-16
Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) 9 was 10 Amended — Page VI-17
Introduced (House)House Bill 1 as introduced (LBB recommended, House) 9 was 10 Amended — Page VI-17
Senate substituteCommittee Substitute for Senate Bill 1 9 Unchanged Amended Page VI-14
House substituteHouse Committee Substitute for Senate Bill 1 9 Unchanged Amended Page VI-15
House passedSenate Bill 1 as passed the second house 9 Unchanged Amended Page VI-15
ConferenceConference Committee Report for Senate Bill 1 9 Unchanged Amended Page VI-15
2026-27 ActGeneral Appropriations Act, 2026-27 Biennium 10 was 9 Unchanged Amended Page VI-16
Full text of each wording

Introduced (Senate), Introduced (House), Senate substitute, House substitute, House passed, Conference, 2026-27 Act

Source, page VI-16

Cattle Fever Tick Mitigation Clinical Trials. Amounts appropriated above to the Animal Health Commission in Strategy A.1.2, Diagnostic/Epidemiological Support Services, include $30,000 in fiscal year 2026 from the General Revenue Fund for the purposes of completing cattle fever tick mitigation clinical trials that would evaluate the efficacy of three eprinomectin regimens for cattle fever tick control to determine if less frequent treatments can be used to effectively mitigate fever ticks. Any unexpended balances remaining as of August 31, 2026, are appropriated in the fiscal year beginning September 1, 2026, for the same purposes.

2024-25 Act

Source, page VI-16

Cattle Fever Tick Mitigation Clinical Trials.

(a) Amounts appropriated above to the Animal Health Commission (TAHC) in Strategy A.1.2, Diagnostic/Epidemiological Support Services, include $87,000 in fiscal year 2024 and $229,000 in fiscal year 2025 from General Revenue for the purposes of conducting cattle fever tick mitigation clinical trials that would evaluate the efficacy of three eprinomectin regimens for cattle fever tick control to determine if less frequent treatments can be used to effectively mitigate fever ticks. Any unexpended balances remaining as of August 31, 2024, are appropriated in the fiscal year beginning September 1, 2024, for the same purposes.

(b) Out of amounts identified in subsection (a), TAHC would evaluate dosing and withdraw periods in weaned beef heifers in phase one.

(c) Out of amounts identified in subsection (a), TAHC shall transfer up to $40,000 of the funds appropriated by this rider in fiscal year 2025 to a Texas state University through an interagency contract to assist in conducting phase two of the clinical trials that would evaluate repeated dosing and withdraw periods in full herd settings.